Article
Rheumatology
Christina Charles-Schoeman, Ernest Choy, Iain B. McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K. Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R. Curtis
Summary: This study provides an integrated analysis of major adverse cardiovascular events (MACEs) and venous thromboembolism (VTE) events in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) patients treated with upadacitinib. The results show that the rates of MACEs and VTE events with upadacitinib are similar to those reported for conventional synthetic and biologic disease-modifying drugs, and comparable to adalimumab and methotrexate.
Article
Rheumatology
Anton Jonatan Landgren, Mats Dehlin, Lennart Jacobsson, Ulrika Bergsten, Eva Klingberg
Summary: The study aimed to compare traditional cardiovascular risk factors among patients with different rheumatic diseases, and found that hypertension was the most common comorbidity, with patients with gout having the highest prevalence of traditional CVRFs. Significant differences in occurrence of CVRFs by sex were also observed among patients with PsA, RA and AS.
Article
Rheumatology
Cindy L. J. Weinstein, Alan G. Meehan, Jianxin Lin, Steven D. Briscoe, Marinella Govoni
Summary: This study analyzed the long-term persistence of golimumab treatment in patients with rheumatic diseases over a period of five years. The findings showed that golimumab had consistently high retention rates when used as first-line therapy and lower rates when used as second-line therapy, with patients on second-line therapy having a longer disease duration.
CLINICAL RHEUMATOLOGY
(2023)
Article
Medicine, General & Internal
Vandana Bhushan, Susan Lester, Liz Briggs, Raif Hijjawi, E. Michael Shanahan, Eliza Pontifex, Jem Ninan, Catherine Hill, Fin Cai, Jennifer Walker, Fiona Goldblatt, Mihir D. Wechalekar
Summary: Similar retention rates of the second and third compared to the first b/tsDMARD in RA, PsA, and AS support a differential b/tsDMARDs use strategy based on patient presentation. The risk of b/tsDMARD failure was halved in PsA patients, and covariates were not associated with the risk of bDMARD failure. The most common reason for switching was treatment failure.
FRONTIERS IN MEDICINE
(2021)
Editorial Material
Rheumatology
Juergen Braun, Dietmar Krause, Uta Kiltz
Summary: This editorial discusses the impact evaluation of a nurse-led program for patient self-assessment and self-management in axial spondyloarthritis, presented in a prospective, multicenter, randomized, controlled trial (COMEDSPA) conducted by Anna Molto et al.
Article
Rheumatology
Gerd R. Burmester, Stanley B. Cohen, Kevin L. Winthrop, Peter Nash, Alan D. Irvine, Atul Deodhar, Eduardo Mysler, Yoshiya Tanaka, John Liu, Ana P. Lacerda, Hannah Palac, Tim Shaw, Philip J. Mease, Emma Guttman-Yassky
Summary: This study evaluated the long-term safety of upadacitinib in patients with RA, PsA, AS, and AD. The analysis of safety data from clinical trials showed that upadacitinib was generally well tolerated in these diseases, with some differences in safety profiles.
Article
Rheumatology
Xabier Michelena, Clementina Lopez-Medina, Alba Erra, Xavier Juanola, Pilar Font-Ugalde, Eduardo Collantes, Helena Marzo-Ortega
Summary: This study compared the clinical and radiographical characteristics of axial psoriatic arthritis (PsA) with ankylosing spondylitis (AS) with psoriasis. It found that axial PsA is predominantly HLA-B27 negative and has different manifestations compared to AS with psoriasis. There is great heterogeneity in the definition of axial PsA from a clinical and imaging perspective.
Article
Biochemistry & Molecular Biology
Krzysztof Bonek, Ewa Kuca Warnawin, Anna Kornatka, Magdalena Plebanczyk, Tomasz Burakowski, Wlodzimierz Maslinski, Malgorzata Wislowska, Piotr Gluszko, Marzena Ciechomska
Summary: This study investigates the associations between miR signatures and cytokines, serum lipids, and disease activity in patients with PsA, AS, and RA. The results show the superiority of miR expressions in distinguishing between RA, PsA, and AS, and a unique regulatory pathway in PsA.
Article
Rheumatology
M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh
Summary: The safety profile of IV golimumab in treating rheumatologic diseases was similar to that of other TNFi, and the concomitant use of methotrexate or corticosteroids was associated with an increase in certain adverse events.
ARTHRITIS RESEARCH & THERAPY
(2022)
Article
Rheumatology
Walter Reinisch, Wayne Hellstrom, Radboud J. E. M. Dolhain, Suresh Sikka, Rene Westhovens, Rajiv Mehta, Timothy Ritter, Ursula Seidler, Oleksandr Golovchenko, Vladimir Simanenkov, Olena Garmish, Slawomir Jeka, Radka Moravcova, Vijay Rajendran, Franck-Olivier Le Brun, Sarah Arterburn, Timothy R. Watkins, Robin Besuyen, Dirk Vanderschueren
Summary: The phase 2 MANTA and MANTA-RAy studies aimed to determine the impact of the oral Janus kinase 1 inhibitor filgotinib on semen parameters and sex hormones in men with inflammatory diseases. Results showed that once daily filgotinib 200 mg for 13 weeks had no measurable impact on semen parameters or sex hormones.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Luis Fernando Perez-Garcia, Esther Roder, Robbert J. Goekoop, Johanna M. W. Hazes, Marc R. Kok, Hieronymus T. W. Smeele, Ilja Tchetverikov, Annette H. M. Van der Helm-van Mil, Jos H. van der Kaap, Petra Kok, Bouwe P. Krijthe, Radboud J. E. M. Dolhain
Summary: This study is the first to demonstrate that inflammatory arthritis can impact male fertility. Men diagnosed with IA before and during the peak reproductive years have lower fertility rates, higher rates of childlessness, and more fertility problems.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Timothy S. H. Kwok, Mitchell Sutton, Daniel Pereira, Richard J. Cook, Vinod Chandran, Nigil Haroon, Robert D. Inman, Dafna D. Gladman
Summary: Isolated axial PsA and AS with psoriasis are relatively uncommon. HLA-B*27 positivity is associated with isolated axial PsA and may predict the development of peripheral disease. Isolated axial PsA is associated with better functional status. Isolated axial PsA appears clinically distinct from isolated axial AS with psoriasis.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Elana Meer, Telma Thrastardottir, Xingmei Wang, Maureen Dubreuil, Yong Chen, Joel M. Gelfand, Thorvardur J. Love, Alexis Ogdie
Summary: This study identified shared and different risk factors for PsA, PsO, RA, and AS, including obesity, alcohol intake, infections, and other factors. Smoking, anemia, inflammatory bowel disease, etc. also had an impact on the onset of RA and AS.
JOURNAL OF RHEUMATOLOGY
(2022)
Article
Rheumatology
Clementina Lopez-Medina, Anna Molto, Joachim Sieper, Tuncay Duruoz, Uta Kiltz, Bassel Elzorkany, Najia Hajjaj-Hassouni, Ruben Burgos-Vargas, Jose Maldonado-Cocco, Nelly Ziade, Meghna Gavali, Victoria Navarro-Compan, Shue-Fen Luo, Sara Monti, Kim Tae-Jong, Mitsumasa Kishimoto, F. M. Pimentel-Santos, Jieruo Gu, Ruxandra Schiotis, Floris A. van Gaalen, Pal Geher, Marina Magrey, Sebastian E. Ibanez Vodnizza, Wilson Bautista-Molano, Walter Maksymowych, Pedro M. Machado, Robert Landew, Desiree van der Heijde, Maxime Dougados
Summary: This study included 4465 patients with SpA from 24 countries around the world, showing quantitative differences in peripheral manifestations among different subtypes but no significant qualitative differences. It was found that a high proportion of patients with SpA had both axial and peripheral manifestations coinciding.
Article
Rheumatology
Adrian Ciurea, Andrea Gotschi, Seraphina Kissling, Alexander Bernatschek, Kristina Burki, Pascale Exer, Michael J. Nissen, Burkhard Moller, Almut Scherer, Raphael Micheroli
Summary: This study compared the characteristics of patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and found differences in demographic and clinical features between the two groups, but a similar disease burden.
